CGC Financial Services’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$93.6K Hold
3,888
0.02% 103
2026
Q1
$109K Sell
3,888
-1,695
-30% -$45.1K 0.03% 90
2025
Q4
$139K Buy
5,583
+2,549
+84% +$64.3K 0.04% 82
2025
Q3
$77.3K Hold
3,034
0.02% 105
2025
Q2
$73.5K Sell
3,034
-88
-3% -$2.05K 0.02% 101
2025
Q1
$79.1K Buy
3,122
+98
+3% +$2.56K 0.03% 90
2024
Q4
$80.2K Hold
3,024
0.03% 87
2024
Q3
$87.5K Buy
3,024
+549
+22% +$16K 0.04% 80
2024
Q2
$69.3K Hold
2,475
0.03% 84
2024
Q1
$68.7K Buy
2,475
+492
+25% +$13.7K 0.04% 86
2023
Q4
$57.1K Hold
1,983
0.03% 99
2023
Q3
$65.8K Hold
1,983
0.05% 75
2023
Q2
$72.7K Buy
+1,983
New +$77.2K 0.05% 77

Other funds holding PFE

CGC Financial Services's PFE Position: Q2 2026 in Review

CGC Financial Services held its Pfizer (PFE) position steady in Q2 2026 at 3,888 shares worth $93.6K. The position accounts for 0.02% of the portfolio, ranked #103.

CGC Financial Services first reported a position in PFE in Q2 2023 and has held it in 13 quarters since. The position peaked at $139K in Q4 2025. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • CGC Financial Services held 3,888 shares of Pfizer worth $93.6K as of Q2 2026.
  • CGC Financial Services left its Pfizer share count unchanged in Q2 2026.
  • Pfizer made up 0.02% of CGC Financial Services's portfolio in Q2 2026, its #103 holding.
  • CGC Financial Services first reported a position in Pfizer in Q2 2023 and has held it in 13 quarters since.
  • CGC Financial Services's Pfizer position peaked at $139K in Q4 2025.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on CGC Financial Services's 13F filing for Q2 2026, filed 13 Jul 2026.